Evaluating predictors of kinase activity of STK11 variants identified in primary human non-small cell lung cancers.

Castrense Savojardo, Akash Kamandula, David J Seward, Yuanfei Sun, Changwon Keum, Junwoo Woo, Kyoungyeul Lee, Yile Chen, Yang Shen, Sean D Mooney, Rita Casadio, Pier Luigi Martelli, Anne O'Donnell-Luria, Matteo Manfredi, Dong-Wook Kim, Predrag Radivojac, Vikas Pejaver, Shantanu Jain, Olivier Lichtarge, Panagiotis Katsonis, Constantina Bakolitsa, Steven E Brenner, Giulia Babbi

Journal: Human genetics 2025;144(2-3):127-142

PMID: 39934475

Abstract

Critical evaluation of computational tools for predicting variant effects is important considering their increased use in disease diagnosis and driving molecular discoveries. In the sixth edition of the Critical Assessment of Genome Interpretation (CAGI) challenge, a dataset of 28 STK11 rare variants (27 missense, 1 single amino acid deletion), identified in primary non-small cell lung cancer biopsies, was experimentally assayed to characterize computational methods from four participating teams and five publicly available tools. Predictors demonstrated a high level of performance on key evaluation metrics, measuring correlation with the assay outputs and separating loss-of-function (LoF) variants from wildtype-like (WT-like) variants. The best participant model, 3Cnet, performed competitively with well-known tools. Unique to this challenge was that the functional data was generated with both biological and technical replicates, thus allowing the assessors to realistically establish maximum predictive performance based on experimental variability. Three out of the five publicly available tools and 3Cnet approached the performance of the assay replicates in separating LoF variants from WT-like variants. Surprisingly, REVEL, an often-used model, achieved a comparable correlation with the real-valued assay output as that seen for the experimental replicates. Performing variant interpretation by combining the new functional evidence with computational and population data evidence led to 16 new variants receiving a clinically actionable classification of likely pathogenic (LP) or likely benign (LB). Overall, the STK11 challenge highlights the utility of variant effect predictors in biomedical sciences and provides encouraging results for driving research in the field of computational genome interpretation.

© 2025. The Author(s).

Address: Department of Biomedical Informatics and Medical Education, University of Washington, Seattle, WA, 98105, USA.; 3billion, 3billion Biotechnology Company, Seoul, South Korea.; Department of Pharmacy and Biotechnology, University of Bologna, 40126, Bologna, Italy.; Department of Electrical and Computer Engineering, Texas A&M University, College Station, TX, 77843, USA.; Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, 77030, USA.; Institute for Genomic Health, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.; Department of Pathology, University of Vermont, Burlington, VT, 5445, USA.; Khoury College of Computer Sciences, Northeastern University, Boston, MA, 02115, USA.; University of California, Berkeley, Berkeley, CA, 94720, USA.; Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.; Broad Center for Mendelian Genomics, Program in Medical and Population Genetics, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, 02142, USA.; Center for Information Technology, National Institutes of Health, Bethesda, MD, 20892, USA. [email protected].; Khoury College of Computer Sciences, Northeastern University, Boston, MA, 02115, USA. [email protected].; The Institute for Experiential AI, Northeastern University, Boston, MA, 02115, USA. [email protected].

Link outs

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.